Stemtech Corp Reports 43% Revenue Decline, Widening Losses, Going Concern Warning, and Massive Dilution
Summary
Stemtech Corp's annual report highlights severe financial challenges, including a 43% revenue drop, widening losses, a going concern warning, and massive shareholder dilution from debt conversions.
Key Events
-
Going Concern Warning Issued
Management and the auditor express substantial doubt about the company's ability to continue as a going concern, citing recurring losses, negative cash flows, an accumulated deficit of $34.9 million, and a working capital deficiency of $10.4 million as of December 31, 2025.
-
Revenue Plummets 43.1%
Net sales for the year ended December 31, 2025, decreased by $2.18 million to $2.88 million, a 43.1% decline from the prior year, primarily due to product stock-outs and supply disruptions.
-
Net Losses Widen
The company's net loss increased to $4.05 million in 2025 from $3.77 million in 2024, driven by lower revenue and continued fixed operating expenses.
-
Massive Post-Balance Sheet Dilution
Between January 1, 2026, and May 26, 2026, the company issued 1.64 billion common shares, increasing total shares outstanding by over 385% to 2.07 billion. These issuances were entirely from convertible debt conversions, providing no cash proceeds to the company.
Analysis
Stemtech Corp's annual report reveals a company in severe financial distress. Revenue plummeted by 43.1% in 2025, and net losses widened. The company explicitly states substantial doubt about its ability to continue as a going concern, citing recurring losses, negative cash flows, and a significant working capital deficiency. Furthermore, the company is in default on certain debt agreements, and its internal controls over financial reporting are deemed ineffective due to multiple material weaknesses. Post-balance sheet, existing shareholders have faced massive dilution of over 385% from convertible debt conversions, with no cash proceeds received by the company. This filing paints a critical picture of operational and financial instability.
At the time of this filing, STEK was trading at $0.00 on OTC in the Trade & Services sector, with a market capitalization of approximately $46.4K. The 52-week trading range was $0.00 to $0.04. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.